Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838124 | 0.91 | CA14 (0.34) | CA14CA12AAK1 | |
| SCHEMBL27612964 | 0.91 | CA14 (0.34) | CA14CA12AAK1 | |
| SCHEMBL19663961 | 0.86 | CA14 (0.40) | CA14CA12AAK1CA1CA2 | |
| SCHEMBL29023150 | 0.84 | CA14 (0.35) | CA14CA12CA1CA2CA7 | |
| SCHEMBL6673738 | 0.84 | GABRR1 (0.33) | CA14AAK1 | |
| SCHEMBL1027531 | 0.83 | AAK1 (0.34) | CA14CA12AAK1CA1CA2 | |
| SCHEMBL708097 | 0.82 | CA14 (0.37) | CA14CA12AAK1CA1CA2 | |
| SCHEMBL708096 | 0.82 | CA14 (0.37) | CA14CA12AAK1CA1CA2 | |
| SCHEMBL5133273 | 0.82 | CA14 (0.34) | CA14CA12 | |
| SCHEMBL2253762 | 0.82 | CA14 (0.34) | CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | PNA Patent Owners (a/k/a CIG) (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1074559-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-7378485-B2 | Peptide nucleic acids with polyamide-containing backbones | BUCHARDT OLE | 2008-05-27 | — | — | US | disclosed |
| US-20060160731-A1 | Peptide nucleic acids | BUCHARDT OLE | 2006-07-20 | — | — | US | disclosed |
| EP-1411063-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2006-07-19 | — | — | EP | disclosed |
| US-20060046255-A1 | Use of nucleic acid analogues in diagnostics and analytical procedures | BUCHARDT OLE | 2006-03-02 | — | — | US | disclosed |
| EP-0960121-B1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT DORTE (DK) | 2005-11-30 | — | — | EP | disclosed |
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | BUCHARDT OLE (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-1411063-A1 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2004-04-21 | — | — | EP | disclosed |
| US-6713602-B1 | COMPOUNDS THAT ARE NOT POLYNUCLEOTIDES YET WHICH BIND TO COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY THE CORRESPONDING DNA | BUCHARDT OLE (DK) | 2004-03-30 | — | — | US | disclosed |
| US-5736336-A | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility | BUCHARDT OLE (DK) | 1998-04-07 | — | — | US | disclosed |
| US-5719262-A | BIND COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY | BUCHARDT OLE (DK) | 1998-02-17 | — | — | US | disclosed |
| US-5714331-A | INCORPORATING AN AMINOALKYL SIDE CHAIN INTO THE PNA'S WHICH BIND TO COMPLEMENTARY NUCLEOBASE SEQUENCES MORE TIGHTLY TO FORM ?DUPLEXES?; VIRICIDES; ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS | EXXON CHEMICAL PATENT INC. | 1998-02-03 | — | — | US | disclosed |
| WO-1998003542-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, DORTE (DK) | 1998-01-29 | — | — | WO | disclosed |
| EP-0586618-B1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT DORTE (DK) | 1997-07-16 | — | — | EP | disclosed |
| US-5539082-A | Peptide nucleic acids | NIELSEN PETER E (DK) | 1996-07-23 | — | — | US | disclosed |
| EP-0586618-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES. | BUCHARDT OLE (DK) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586474-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT, Ole (DK) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020703-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115136-A1 | PNA DIAGNOSTIC USE | RNASE1, NCL, PABPC4 | CA14 61/4885CA12 98/4885AAK1 4084/4885 |
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | POLRMT, CPSF7, RNGTT | CA14 2444/4885CA12 3334/4885AAK1 2696/4885 |
| US-20060046255-A1 | Use of nucleic acid analogues in diagnostics and analytical procedures | ADAR, POLRMT, POLI | CA14 133/4885CA12 210/4885AAK1 4368/4885 |
| US-20060160731-A1 | Peptide nucleic acids | RNGTT, POLM, POLRMT | CA14 2627/4885CA12 3022/4885AAK1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.